



Cellular Therapy & Immunobiology Working Party

Chair: Annalisa Ruggeri
Secretary: Florent Malard
Vice-chair: Jürgen Kuball

Statistician: Jarl Mooyaart, Ed Bonneville
Study Coordinator: Jorinde Hoogenboom
Data manager: Jeroen Knippenberg

CTIWP

The mission of the CTIWP is to understand and exploit the biological and immunological events occurring upon HSCT at large, and to implement modern cellular therapies (CTs) based on cell and gene engineering approaches to improve patient outcomes. The CTIWP aims at fostering CT in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of CT approaches to answer unmet medical needs.

Educational events in 2023


- Joint CMWP-CTIWP educational meeting
- 5th EBMT/EHA European CAR T-Cell hybrid Meeting

CELLULAR THERAPY REGISTRY

The Cellular Therapy Form was originally designed to collect data on stem cells, progenitors or mature cells, such as T-lymphocytes, unmanipulated, such as DLI, or sorted and/or cultured and/or genetically manipulated, such as CAR T-cells, used for treatment in combination with HSCT or alone, and including advanced therapeutic medicinal products (ATMP), as well as data on the clinical characteristics and outcomes of the patients. It has been revised with the primary focus on collecting data on CAR-T cells treated patient and adapted to the evolving IT now deployed to support the EBMT registry.

PLEASE CONTRIBUTE... AND REPORT YOUR PATIENTS

Number of CAR T-cell treated patients registered in the EBMT Registry



Source: EBMT Registry, July 2023

*Patients identified and marked with a CAR T-cell treatment, having at least minimal data on the diagnosis and treatment.

KEY PUBLICATIONS 2023

Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT
G. Battipaglia et al., Bone Marrow Transplantation, 2023 Dec;58(12):1419-1421

Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party
R. Greco et al., Bone Marrow Transplantation, 2023 May;58(5):603-606

Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party
M. De Witte et al., Bone Marrow Transplantation, 2023 Jun;58(6):719-722

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
P. Comoli et al., Annals of Oncology, 2023 Dec;S0923-7534(23)05116-5

+ see all CTIWP publications on: <https://www.ebmt.org/research/publications>

IEC FORUM FOR NURSES

The aim of the forum is to create a global support network for nurses and allied health professionals (AHPs) involved in the care of patients being treated or potentially being treated with Immune Effector Cell Therapy at all stages of the patient pathway. Learn more:

<https://www.ebmt.org/immune-effector-cell-forum>

CTIWP at 50th Annual Meeting of EBMT

Monday, April 15th

Cell Therapy Day
09:00-17:45 LOMOND

Tuesday, April 16th

Scientific Business Meeting (on-site)
12:45 – 14:00 Room: FORTH

Cellular Therapy and Immunobiology Working Party Session including the Jon J. van Rood Award presentation
09:00 – 10:15 Room: Hall 5

Oral presentations

1. *Esteban Arrieta Bolaños* – HLA mismatching and survival after HCT in the PTCY era: a comprehensive study by the EBMT CTIWP;
2. *Antoine Capes* - PTCY Plus ATG Compared To PTCY Alone In Hapoidentical Transplantation With Pbscs: A Retrospective Study On Behalf Of The CTIWP Of The EBMT;

Poster presentations

1. *Paolo Pedrazzoli* – High-dose chemotherapy with stem cell transplantation in adult primary mediastinal germ cell tumors. A retrospective study of the EBMT, CTIWP;
2. *Florent Malard* - Choice of commercially available CAR T-cells product for aggressive lymphoma: a survey of behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT;

CURRENT STUDIES

- Associations between HLA Evolutionary Divergence and clinical outcome of matched related or unrelated stem cell transplantation (P. Crivello)
- Current use of donor lymphocyte infusions after allogeneic stem cell transplantation: a survey on behalf of the CTIWP of the EBMT (N. Santoro)
- Frequency of CAR-T cell manufacturing failures and Out-of-Specification products in the real-world setting (N. Worel)
- Defining protective T-cell thresholds following allogeneic HSCT (M. Cavazzana)
- MSCs for treatment of steroid-resistant acute GvHD (L. van Hussen-Daenen)
- State-of-the art of immune monitoring procedures after chimeric antigen receptor T-cell therapies in EBMT centers (S. Pagliuca)
- PTCY Plus ATG Compared To PTCY Alone In Hapoidentical Transplantation With Pbscs: A Retrospective Study On Behalf Of The CTIWP Of The EBMT (A. Capes)

+ see all CTIWP studies on: <https://www.ebmt.org/research/studies>

UPCOMING EVENTS

EBMT

Immunology and Cellular Therapies in Autoimmune Diseases
Milan, Italy
10-12 October 2024

Organisers:
Autoimmune Diseases Working Party:
Raffaella Greco, Tobias Alexander
Cellular Therapy & Immunobiology Working Party:
Annalisa Ruggeri, Florent Malard
Local Organiser:
Jürgen Kuball

SAVE THE DATE

CONTACT CTIWP

Would you like to receive information on our studies, submit a study protocol, or become a CTIWP member and help advance our research? Feel free to contact us at: ctiwpebmt@lumc.nl